The Warburg effect and its cancer therapeutic implications

[1]  J. Chesney.  6-Phosphofructo-2-kinase/fructose-2,6-bisphosphatase and tumor cell glycolysis , 2006, Current opinion in clinical nutrition and metabolic care.

[2]  Saroj P. Mathupala,et al.  Hexokinase II: Cancer's double-edged sword acting as both facilitator and gatekeeper of malignancy when bound to mitochondria , 2006, Oncogene.

[3]  N. Hay,et al.  Mitochondrial hexokinases, novel mediators of the antiapoptotic effects of growth factors and Akt , 2006, Oncogene.

[4]  H. Pelicano,et al.  Glycolysis inhibition for anticancer treatment , 2006, Oncogene.

[5]  Marty C. Brandon,et al.  Mitochondrial mutations in cancer , 2006, Oncogene.

[6]  Eyal Gottlieb,et al.  TIGAR, a p53-Inducible Regulator of Glycolysis and Apoptosis , 2006, Cell.

[7]  Oksana Gavrilova,et al.  p53 Regulates Mitochondrial Respiration , 2006, Science.

[8]  P. Leder,et al.  Attenuation of LDH-A expression uncovers a link between glycolysis, mitochondrial physiology, and tumor maintenance. , 2006, Cancer cell.

[9]  R. Moreno-Sánchez,et al.  Determining and understanding the control of glycolysis in fast‐growth tumor cells , 2006, The FEBS journal.

[10]  K. Ginalski,et al.  Efficacy of 2-halogen substituted d-glucose analogs in blocking glycolysis and killing “hypoxic tumor cells” , 2006, Cancer Chemotherapy and Pharmacology.

[11]  G. Semenza,et al.  HIF-1-mediated expression of pyruvate dehydrogenase kinase: a metabolic switch required for cellular adaptation to hypoxia. , 2006, Cell metabolism.

[12]  H. Pelicano,et al.  Synergistic effect of targeting mTOR by rapamycin and depleting ATP by inhibition of glycolysis in lymphoma and leukemia cells , 2005, Leukemia.

[13]  Eyal Gottlieb,et al.  Mitochondrial tumour suppressors: a genetic and biochemical update , 2005, Nature Reviews Cancer.

[14]  T. Lazar Mathew,et al.  Optimizing Cancer Radiotherapy with 2-Deoxy-D-Glucose , 2005, Strahlentherapie und Onkologie.

[15]  K. Takata,et al.  Hexokinase-II expression in untreated oral squamous cell carcinoma: Comparison with FDG PET imaging , 2005, Annals of nuclear medicine.

[16]  M. Sirover.  New nuclear functions of the glycolytic protein, glyceraldehyde‐3‐phosphate dehydrogenase, in mammalian cells , 2005, Journal of cellular biochemistry.

[17]  S. Schreiber,et al.  Perturbational profiling of a cell-line model of tumorigenesis by using metabolic measurements , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[18]  Peng Huang,et al.  Inhibition of glycolysis in cancer cells: a novel strategy to overcome drug resistance associated with mitochondrial respiratory defect and hypoxia. , 2005, Cancer research.

[19]  Okio Hino,et al.  A mutation in the SDHC gene of complex II increases oxidative stress, resulting in apoptosis and tumorigenesis. , 2005, Cancer research.

[20]  Manuel Hidalgo,et al.  Matrix metalloproteinase-2 contributes to cancer cell migration on collagen. , 2005, Cancer research.

[21]  K. Greulich,et al.  Genes of glycolysis are ubiquitously overexpressed in 24 cancer classes. , 2004, Genomics.

[22]  Martin G Pomper,et al.  Advanced cancers: eradication in all cases using 3-bromopyruvate therapy to deplete ATP. , 2004, Biochemical and biophysical research communications.

[23]  R. Gillies,et al.  Why do cancers have high aerobic glycolysis? , 2004, Nature Reviews Cancer.

[24]  S. Gottschalk,et al.  Imatinib (STI571)-Mediated Changes in Glucose Metabolism in Human Leukemia BCR-ABL-Positive Cells , 2004, Clinical Cancer Research.

[25]  Keshav K. Singh.  Mitochondrial Dysfunction Is a Common Phenotype in Aging and Cancer , 2004, Annals of the New York Academy of Sciences.

[26]  G. Giaccone,et al.  Glufosfamide administered by 1-hour infusion as a second-line treatment for advanced non-small cell lung cancer; a phase II trial of the EORTC-New Drug Development Group. , 2004, European Journal of Cancer.

[27]  Awtar Krishan,et al.  Greater cell cycle inhibition and cytotoxicity induced by 2-deoxy-d-glucose in tumor cells treated under hypoxic vs aerobic conditions , 2004, Cancer Chemotherapy and Pharmacology.

[28]  N. Savaraj,et al.  2-Deoxy-d-glucose Increases the Efficacy of Adriamycin and Paclitaxel in Human Osteosarcoma and Non-Small Cell Lung Cancers In Vivo , 2004, Cancer Research.

[29]  D. Lacombe,et al.  Glufosfamide administered using a 1-hour infusion given as first-line treatment for advanced pancreatic cancer. A phase II trial of the EORTC-new drug development group. , 2003, European journal of cancer.

[30]  P. Hammerman,et al.  Akt-Directed Glucose Metabolism Can Prevent Bax Conformation Change and Promote Growth Factor-Independent Survival , 2003, Molecular and Cellular Biology.

[31]  S. Grimm,et al.  The tumor suppressor cybL, a component of the respiratory chain, mediates apoptosis induction. , 2003, Molecular biology of the cell.

[32]  Peng Huang,et al.  Mitochondrial DNA mutations in primary leukemia cells after chemotherapy: clinical significance and therapeutic implications , 2003, Leukemia.

[33]  John Eric Wilson.  Isozymes of mammalian hexokinase: structure, subcellular localization and metabolic function , 2003, Journal of Experimental Biology.

[34]  Paolo Carlini,et al.  Lonidamine: efficacy and safety in clinical trials for the treatment of solid tumors. , 2003, Drugs of today.

[35]  N. Savaraj,et al.  Hypoxia increases tumor cell sensitivity to glycolytic inhibitors: a strategy for solid tumor therapy (Model C). , 2002, Biochemical pharmacology.

[36]  Peng Huang,et al.  Mitochondrial defects in cancer , 2002, Molecular Cancer.

[37]  P. Bruzzi,et al.  Time to progression in metastatic breast cancer patients treated with epirubicin is not improved by the addition of either cisplatin or lonidamine: final results of a phase III study with a factorial design. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[38]  Saroj P. Mathupala,et al.  Mitochondrial bound type II hexokinase: a key player in the growth and survival of many cancers and an ideal prospect for therapeutic intervention. , 2002, Biochimica et biophysica acta.

[39]  P. Pedersen,et al.  Novel therapy for liver cancer: direct intraarterial injection of a potent inhibitor of ATP production. , 2002, Cancer research.

[40]  C. Schmidt.  Bench and Bedside , 2002, Molecular Cancer.

[41]  P. Pedersen,et al.  Glucose catabolism in the rabbit VX2 tumor model for liver cancer: characterization and targeting hexokinase. , 2001, Cancer letters.

[42]  I. Roninson,et al.  Growth retardation and increased apoptosis in mice with homozygous disruption of the Akt1 gene. , 2001, Genes & development.

[43]  E. Kandel,et al.  Inhibition of early apoptotic events by Akt/PKB is dependent on the first committed step of glycolysis and mitochondrial hexokinase. , 2001, Genes & development.

[44]  N. Savaraj,et al.  Hypersensitization of tumor cells to glycolytic inhibitors. , 2001, Biochemistry.

[45]  R. Moreno-Sánchez,et al.  Substrate oxidation and ATP supply in AS-30D hepatoma cells. , 2000, Archives of biochemistry and biophysics.

[46]  John Eric Wilson,et al.  Characterization of the Rat Type III Hexokinase Gene Promoter , 1999, The Journal of Biological Chemistry.

[47]  M. Cascante,et al.  Oxythiamine and dehydroepiandrosterone induce a G1 phase cycle arrest in Ehrlich's tumor cells through inhibition of the pentose cycle , 1999, FEBS letters.

[48]  T. Bruno,et al.  Enhancement of doxorubicin content by the antitumor drug lonidamine in resistant Ehrlich ascites tumor cells through modulation of energy metabolism. , 1998, Biochemical pharmacology.

[49]  V. Bakanauskas,et al.  Effect of oncogene transformation of rat embryo cells on cellular oxygen consumption and glycolysis. , 1997, Biochemical and biophysical research communications.

[50]  Karl Brand,et al.  Aerobic glycolysis by proliferating cells: a protective strategy against reactive oxygen species 1 , 1997, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[51]  B. Burgering,et al.  Protein kinase B (c-Akt) in phosphatidylinositol-3-OH kinase signal transduction , 1995, Nature.

[52]  Saroj P. Mathupala,et al.  Glucose Catabolism in Cancer Cells. , 1995, The Journal of Biological Chemistry.

[53]  P. Pedersen,et al.  Glucose catabolism in African trypanosomes. Evidence that the terminal step is catalyzed by a pyruvate transporter capable of facilitating uptake of toxic analogs. , 1993, The Journal of biological chemistry.

[54]  H. Terada,et al.  Remarkably enhanced expression of the type II hexokinase in rat hepatoma cell line AH130 , 1991, FEBS letters.

[55]  P. Pedersen,et al.  Functional significance of mitochondrial bound hexokinase in tumor cell metabolism. Evidence for preferential phosphorylation of glucose by intramitochondrially generated ATP. , 1988, The Journal of biological chemistry.

[56]  H. Lodish,et al.  Elevated levels of glucose transport and transporter messenger RNA are induced by ras or src oncogenes. , 1987, Science.

[57]  P. Pedersen,et al.  Contributions of glycolysis and oxidative phosphorylation to adenosine 5'-triphosphate production in AS-30D hepatoma cells. , 1984, Cancer research.

[58]  B. Silvestrini,et al.  Lonidamine, a selective inhibitor of aerobic glycolysis of murine tumor cells. , 1981, Journal of the National Cancer Institute.

[59]  G. Brierley,et al.  Induction of K+ transport in isolated heart mitochondria by zinc ions. , 1966, Biochemical and biophysical research communications.

[60]  O. Warburg.  [Origin of cancer cells]. , 1956, Oncologia.

[61]  P. Schubert,et al.  Mutations in the transketolase-like gene TKTL1: clinical implications for neurodegenerative diseases, diabetes and cancer. , 2005, Clinical laboratory.

[62]  David G. Watson,et al.  Succinate links TCA cycle dysfunction to oncogenesis by inhibiting HIF-alpha prolyl hydroxylase. , 2005, Cancer cell.

[63]  L. Boros,et al.  Detection of Resistance to Imatinib by Metabolic Profiling , 2005, American journal of pharmacogenomics : genomics-related research in drug development and clinical practice.

[64]  D. McConkey,et al.  Increased mitochondrial biogenesis in primary leukemia cells: the role of endogenous nitric oxide and impact on sensitivity to fludarabine , 2004, Leukemia.

[65]  B. Teicher,et al.  Effect of lonidamine on the cytotoxicity of four alkylating agents in vitro , 2004, Cancer Chemotherapy and Pharmacology.

[66]  Adrian L. Harris,et al.  Hypoxia — a key regulatory factor in tumour growth , 2002, Nature Reviews Cancer.